New England Journal of Medicine· 2022Q1· Clinical trial

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg, Deepak L. Bhatt, Ted R. Mikuls, Gary G. Koch et al.

1,733citations
Q1SCImago
2022year

Short summary

Tofacitinib, a drug for rheumatoid arthritis, was found to increase the risk of major adverse cardiovascular events (MACE) and cancers compared to TNF inhibitors. The drug did not meet noninferiority criteria for safety.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Rheumatology

RheumatologyMedicine